77303-08-3

Usage

Structure

Benzimidazole derivative with a butyl and methyl substituent at the 2 and 4 positions, respectively

Potential applications

Pharmaceutical industry

Pharmacological properties

Antiviral, anticancer, and anti-inflammatory activities

Note

Further research is needed to fully understand the potential uses and properties of 1H-Benzimidazole,2-butyl-4-methyl-(9CI) and its derivatives.

Upstream product

• 13820-09-2 trimethyl orthovalerate 
• 2687-25-4 3-methyl-1,2-benzenediamine 
• 109-52-4 valeric acid 

Downstream Products

• 133224-95-0 4'-(2-Butyl-4-methyl-benzoimidazol-1-ylmethyl)-biphenyl-2-carboxylic acid tert-butyl ester 
• 142219-19-0 (S) Methyl 1-[2-[[4-[(2-butyl-4-methyl-1H-benzimidazol-1-yl)methyl]phenyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-1H-pyrrole-2-carboxylate 
• 142219-34-9 4-<(2-butyl-4-methyl-1H-benzimidazol-1-yl)methyl>benzenamine 
• 142219-33-8 2-butyl-4-methyl-1-<(4-nitrophenyl)methyl>-1H-benzimidazole 

Relevant academic research and scientific papers

A mild, efficient and one-pot synthesis of 2-substituted benzimidazoles by ZrOCl2. 8H2O catalyzed ring closure reaction

A mild, efficient and one-pot synthesis of an array of 2-substituted benzimidazoles from an appropriate o-phenylenediamine and orthoesters such as orthoformate, orthoacetate and orthovalerate using ZrOCl2-8H 2O, at room temperature and under microwave irradiation is described. Ecofriendly, solvent-free methodology has been employed under microwave condition. Compared with the conventional method, microwave irradiation method has the advantages of excellent yields (81-93%) and shorter reaction time (5-10 min).

A highly effective sulfamic acid/methanol catalytic system for the synthesis of benzimidazole derivatives at room temperature

Sulfamic acid/methanol was found to be an efficient catalytic system for the synthesis of benzimidazole compounds through the condensation of o-phenylenediamine with orthoester in high yields at room temperature.

6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships

Starting from the recently reported nonpeptidic angiotensin II (AII) receptor antagonists DuP 753 (1) and Exp 7711 (2), we have designed and investigated novel substituted benzimidazoles. Systematic variation of several substituents at the benzimidazole ring positions 4-7 led to the finding that substitution in position 6 with acylamino groups results in highly active AII antagonists. Compounds with 6-membered lactam or sultam substituents in position 6 of benzimidazole showed receptor activities in the low nanomolar range but were only weakly active when given orally to rats. In contrast, analogous substitution of the benzimidazole moiety with basic heterocycles resulted in potent AII antagonists which were also well absorbed after oral application. The most active compound of this series, 33 (BIBR 277), was selected as a candidate for clinical development. On the basis of molecular modeling studies a binding model of this new class of AII antagonists to the AT1 receptor is proposed.

Substituted benzimidazoles as angiotensin II antagonists

There are disclosed new substituted benzimidazole compounds and derivatives thereof which are useful as angiotensin II antagonists. These compounds have the general formula: